Vontobel Holding Ltd. Acquires 3,202 Shares of BioMarin Pharmaceutical Inc. $BMRN

Vontobel Holding Ltd. increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 68.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,901 shares of the biotechnology company’s stock after acquiring an additional 3,202 shares during the quarter. Vontobel Holding Ltd.’s holdings in BioMarin Pharmaceutical were worth $434,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its holdings in BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after acquiring an additional 1,083,512 shares during the period. Covea Finance raised its holdings in BioMarin Pharmaceutical by 27.3% in the 2nd quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock worth $7,437,000 after acquiring an additional 29,000 shares during the period. GAMMA Investing LLC raised its holdings in BioMarin Pharmaceutical by 154.0% in the 1st quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 1,897 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in BioMarin Pharmaceutical by 12.3% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 97,261 shares of the biotechnology company’s stock worth $6,875,000 after acquiring an additional 10,687 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in BioMarin Pharmaceutical by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,064,924 shares of the biotechnology company’s stock worth $75,279,000 after acquiring an additional 9,837 shares during the period. Institutional investors own 98.71% of the company’s stock.

Analyst Ratings Changes

BMRN has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. boosted their price objective on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Wedbush restated an “outperform” rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. HC Wainwright assumed coverage on shares of BioMarin Pharmaceutical in a report on Monday, September 8th. They set a “neutral” rating and a $60.00 price objective on the stock. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Thirteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $93.26.

BioMarin Pharmaceutical Stock Performance

BMRN stock opened at $52.47 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The company has a 50 day moving average price of $56.02 and a 200 day moving average price of $57.82. BioMarin Pharmaceutical Inc. has a fifty-two week low of $51.56 and a fifty-two week high of $73.51. The stock has a market capitalization of $10.07 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.